Algernon Pharmaceuticals Inc AGNPF

Primary Symbol: C.AGN

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc > New CEO interview

<< Previous

Bullboard Posts

Next >>

Post by StockHawk1on Jan 20, 2023 4:44pm

132 Views

Post# 35236562

New CEO interview

Algernon Pharmaceuticals' (AGN.c AGNPF) CEO, Chis Moreau, went on the Radius Research YT channel yesterday to talk about the company's DMT Program.

AGN has started its Phase 1 DMT Clinical Stroke Study. AGN has already started dosing healthy patients with DMT to identify a safe and tolerable non-psychedelic dose.

In Phase 2 AGN will study how these low doses of DMT affect stroke survivors.